JP2012532596A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532596A5
JP2012532596A5 JP2012519013A JP2012519013A JP2012532596A5 JP 2012532596 A5 JP2012532596 A5 JP 2012532596A5 JP 2012519013 A JP2012519013 A JP 2012519013A JP 2012519013 A JP2012519013 A JP 2012519013A JP 2012532596 A5 JP2012532596 A5 JP 2012532596A5
Authority
JP
Japan
Prior art keywords
plasmin
plasminogen
amino acid
variant
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519013A
Other languages
English (en)
Japanese (ja)
Other versions
JP5819293B2 (ja
JP2012532596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/059902 external-priority patent/WO2011004011A1/en
Publication of JP2012532596A publication Critical patent/JP2012532596A/ja
Publication of JP2012532596A5 publication Critical patent/JP2012532596A5/ja
Application granted granted Critical
Publication of JP5819293B2 publication Critical patent/JP5819293B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519013A 2009-07-10 2010-07-09 プラスミノーゲンおよびプラスミンの変異体 Expired - Fee Related JP5819293B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22451409P 2009-07-10 2009-07-10
EP09165237.0 2009-07-10
US61/224,514 2009-07-10
EP09165237 2009-07-10
PCT/EP2010/059902 WO2011004011A1 (en) 2009-07-10 2010-07-09 Variants of plasminogen and plasmin

Publications (3)

Publication Number Publication Date
JP2012532596A JP2012532596A (ja) 2012-12-20
JP2012532596A5 true JP2012532596A5 (https=) 2013-05-30
JP5819293B2 JP5819293B2 (ja) 2015-11-24

Family

ID=40972886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519013A Expired - Fee Related JP5819293B2 (ja) 2009-07-10 2010-07-09 プラスミノーゲンおよびプラスミンの変異体

Country Status (13)

Country Link
US (1) US9226953B2 (https=)
EP (1) EP2451835A1 (https=)
JP (1) JP5819293B2 (https=)
KR (1) KR20120050442A (https=)
CN (1) CN102482338B (https=)
AU (1) AU2010270146B9 (https=)
CA (1) CA2767612A1 (https=)
IL (1) IL217113A0 (https=)
MX (1) MX2012000475A (https=)
NZ (1) NZ597452A (https=)
RU (1) RU2564131C2 (https=)
WO (1) WO2011004011A1 (https=)
ZA (1) ZA201200191B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
ES2628321T3 (es) * 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
US9730888B2 (en) * 2013-03-14 2017-08-15 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
EP2821081A1 (en) 2013-07-05 2015-01-07 ResuSciTec GmbH Protective solution for preventing or reducing reperfusion injury of the brain and the whole body
DE102014107567B3 (de) * 2014-05-28 2015-11-05 Papierfabrik August Koehler Se Wärmeempfindliches Aufzeichnungsmaterial
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
RU2597782C1 (ru) * 2015-08-25 2016-09-20 Василий Николаевич Яковлев Способ определения содержания продуктов протеолиза в плазме крови и диагностическая тест-система для его осуществления
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
WO2017101869A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗肝组织损伤及其相关病症的方法
CA3008185C (en) * 2015-12-18 2024-01-16 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
CN106890320A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
WO2017101873A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
TWI624268B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
JP6876066B2 (ja) 2015-12-18 2021-05-26 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 子宮膣部びらんを予防及び治療するための方法
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
CN108210917A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
CN108210896A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗高脂血症的药物及其用途
JP7175270B2 (ja) 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
EP3556386A4 (en) * 2016-12-15 2020-07-08 Talengen International Limited METHOD FOR PREVENTING AND TREATING MEDICINALLY INDUCED KIDNEY INJURY
US11154595B2 (en) 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
WO2018107688A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
CN108210897A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肺纤维化的药物及其用途
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
EP3967322B1 (en) * 2019-05-10 2025-03-05 Talengen International Limited Plasminogen for treating amyotrophic lateral sclerosis
KR20220156934A (ko) * 2020-03-24 2022-11-28 탈렌젠 인터내셔널 리미티드 잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물
CN115697385A (zh) 2020-05-11 2023-02-03 泰伦基国际有限公司 一种治疗脊髓性肌萎缩症的方法和药物
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
CN113755476B (zh) * 2021-10-14 2023-04-11 北京农学院 蛆激酶制备方法及其用途
CN119331857B (zh) * 2024-12-19 2025-05-16 南通大学 一种新型重组蛋白Plasminogen-CTM及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3208908A (en) 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US4122158A (en) 1976-09-23 1978-10-24 Alza Corporation Topical therapeutic preparations
NZ191320A (en) 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
IT1194135B (it) 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
WO1990013640A1 (en) 1989-05-01 1990-11-15 The University Of Notre Dame Du Lac Methods and materials for expression of human plasminogen in a eukaryotic cell system
US5087572A (en) 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
AT402367B (de) 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US5288489A (en) 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
EP0835931A4 (en) 1995-06-26 2000-11-15 Daiichi Pure Chemicals Co Ltd STABLE PLASMINE SOLUTION
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
ATE349226T1 (de) 1998-09-29 2007-01-15 Leuven Res & Dev Vzw Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US6585972B2 (en) 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US20040081643A1 (en) 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
JP4297207B2 (ja) 1999-07-14 2009-07-15 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルク 止血障害処置のための治療組成物に使用するためのリガンド
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
WO2001058921A2 (en) 2000-02-08 2001-08-16 Northwestern University Methods and compositions for generating angiostatin
JP4047170B2 (ja) * 2000-12-21 2008-02-13 トロム−イクス・ナムローゼ・フエンノートシャップ 酵母発現ベクターおよび酵母細胞における発現による組換えタンパク質の製造方法
US20020139378A1 (en) 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
AU2003210137A1 (en) 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
US20040235115A1 (en) 2002-11-18 2004-11-25 Reed Guy L. Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CA2535489C (en) 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
CN1938427A (zh) * 2004-02-11 2007-03-28 比奥莱克斯公司 纤溶酶原和微纤溶酶原在浮萍中的表达
CN1253560C (zh) 2004-03-01 2006-04-26 宁夏大学 组织型纤溶酶原激活剂缺失/点突变体基因转染细胞株
CN102660564B (zh) 2004-04-22 2013-05-08 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007047874A2 (en) 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20070134230A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070134231A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
AU2007290881B2 (en) 2006-08-28 2013-03-07 Omnio Healer Ab Candidates against infection
CN101730740A (zh) 2006-09-29 2010-06-09 蛋白质组技术公司 用于生产重组纤溶酶原和纤溶酶多肽的方法
PL2220221T3 (pl) 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
WO2009073457A1 (en) 2007-11-30 2009-06-11 Bausch & Lomb Incorporated Methods and compositions for the rescue of a filtering bleb
WO2011004011A1 (en) 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants

Similar Documents

Publication Publication Date Title
JP2012532596A5 (https=)
RU2012103949A (ru) Варианты плазминогена и плазмина
RU2604807C2 (ru) Варианты плазминогена и плазмина
JP6000353B2 (ja) プラスミノーゲンおよびプラスミンの変異体
CA2904444A1 (en) Dual reactivity potent kunitz inhibitor of fibrinolysis
HK1191054A (en) Plasminogen and plasmin variants
HK1191054B (en) Plasminogen and plasmin variants
HK1193747A (en) Plasminogen and plasmin variants
CN1560240A (zh) 组织型纤溶酶原激活剂缺失突变体基因转染细胞株
HK1167265B (en) Variants of plasminogen and plasmin